Current Topics
In Race for Biodefense Countermeasures, Diagnostics Downplayed
Despite heightened surveillance and intensified efforts to develop new therapies, vaccines, and other biodefense countermeasures, the development and deployment of better diagnostic and monitoring procedures continue to be among the weak links in the overall U.S. biodefense strategy, according to several participants who spoke during the opening session of the 2005 ASM Biodefense Research Meeting, held in Washington, D.C., last February.
Since 2001, experts have repeatedly reviewed and considered how to respond to various bioterrorist attack scenarios, but each such review seems to uncover one or another gap where monitoring and surveillance efforts might not detect an event-a bioterrorist attack or emergence of a novel infectious disease-until it is well under way, according to Mary Gilchrist of the University of Iowa, Iowa City. For example, biosensors might not work properly, and the pathogens responsible for many kinds of respiratory illnesses may be difficult to identify or, in the case of gastrointestinal (GI) illnesses, may rarely be tested for, she says.
Iowa has a primarily agriculturally based economy, and thus its farm animal population includes more than 14 million pigs and at least 1 million chickens, according to Gilchrist. "Diseases are emerging all the time in Iowa, but a lot of them are not being diagnosed," she says. If the priority is not to overlook the most important infectious disease events amid these potentially confounding background signals, perhaps it would make sense to harness what she calls the "best biosensor"-namely, humans-for detecting bioterrorist attacks. She recommends rapid, syndrome-based testing of specimens from individuals with either respiratory or GI symptoms as being "more effective than a lot of other testing" that now is being done for the sake of surveillance against bioterrorism.
However, others are quick to point out that syndromic testing should not be disconnected from efforts to identify true etiologic agents. It is a "big issue," says C. J. Peters of the University of Texas Medical Branch, Galveston.
"Why are we investing so little in diagnostics?" Peters asks. Having a rich array of reliable point-of-care diagnostics is an "extremely important" challenge, and one that should be brought to the "forefront," he says.
Although good point-of-care tests would be welcome, many that are now available yield too many falsepositive or -negative results, Gilchrist points out. "This field is not solving our problems in many cases because the tests are leading people down the wrong alley." In effect, we become the "victims" of bad tests when their results prove unreliable, she adds.
Another reason that diagnostics are not being more intensively developed can be blamed on the "culture of empiricism-that we don't need to know what the microbe is to treat patients," says Arturo Casadevall of the Albert Einstein Medical School in Bronx, N.Y. Physicians typically begin treating patients with antibiotics without determining what is causing their infectious-disease symptoms. However, he notes, as antibiotic resistance becomes an ever-more-important problem in clinical settings, physicians are beginning again to demand better diagnostic tests.
Meanwhile, a good deal of surveillance involves testing at the state and regional levels through the national Laboratory Response Network (LRN) that the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga., coordinates. Despite its critical role, the "LRN is a bit of an orphan," faced with chronic shortfalls, including funds for necessary reagents, Gilchrist says. "How will it manage if there is a large outbreak?" Several years ago Renata Pasqualini and Wadih Arap of M.D. Anderson showed that tissues within the human vascular system contain highly specific molecular signatures, which they refer to as "zip codes." Taking advantage of that specificity, they recently engineered the DNA of phages to display peptides that recognize and bind to particular zip codes once they reach specific tissues.
Gold
They couple these phage to gold nanoparticles, which are biologically compatible and have properties that are useful for imaging. Moreover, the gold particles can be linked to several phage at once, which enhances the binding to tissues of interest. The gold also can effectively bind drugs or harbor stem cells to be delivered to specific tissues.
When mixed, gold and the phage are brought together by their opposite electric charges to form a hydrogel. For use in imaging or drug delivery, the hydrogel is broken up, and gold-phage particles are purified from the mix.
For other uses, hydrogels can provide a three-dimensional space-for example, in which to grow cells, including stem cells, according to Pasqualini. In this case, the hydrogel also contains peptides that stud the phage surfaces. "Cells like to cling to things as they grow," she says. "In tissues, proteins anchor cells, and help them grow. Here we have an artificial matrix in which cells can grow and proliferate. This is a much more physiologic environment than a plastic dish." Hydrogels containing appropriate stem cells could be injected directly into injury sites, where "the stem cells could potentially morph into tissue needed to internally repair the wound," she points out.
"People all over the world have been trying to target gold particles for a long time, to make them selectively bind to different cells," Pasqualini continues. But until now, the technology has defied efforts to incorporate such biologically useful specificities. "In this system, they come together almost spontaneously, in a biological way, solving a problem that has caused a lot of work and frustration." "This is a breakthrough because alternative technologies for these purposes are expensive and impractical," says Glauco R. Souza, a postdoc who works with Pasqualini and Arap. For example, the synthetic peptides that are used in a leading alternative "are expensive, and the chemistry is complex, requiring very toxic solvents, and a purification process," he says.
However, others remain a bit skeptical, albeit hopeful about where this technology is headed. "There is a long way to go to make this useful," says Michael R. Zachariah of the University of Maryland in College Park and the National Institute of Standards and Technology in Gaithersburg, Md. "But that is true with all of these nanomedicine methods. My feeling is that the phage display technology does targeting as well as, if not better, than any other technology. The approach in this paper is at least as exciting as what has come before."
David Holzman
David Holzman is the Microbe Journal Highlights Editor.
Rumen Protozoa Boost Salmonella Virulence, Foster Gene Exchanges
When protozoa engulf, they typically also digest that ingested bacteria, except in the case of Salmonella. Remarkably, some strains of these bacteria become more virulent when consumed by protozoa that inhabit the rumen of cattle, according to researchers at the National Animal Dis- When calves become infected with DT104, they are 13 times more likely to die-while humans infected with DT104 are 2 to 3 times more likely to be hospitalized-than if they were infected with antibiotic-sensitive strains. A cluster of genes, called Salmonella genomic island 1 (SGI1), in DT104 encodes resistance to several types of antibiotics.
After DT104 is mixed with rumen fluid containing protozoa, it proves an unusually potent pathogen for neonatal calves exposed to it, according to the NADC researchers. Such animals develop rapidly progressing, disseminated Salmonella infections. Moreover, the strain appears to become hypervirulent after exposure to protozoa, as measured by its ability to infect cultures of intestinal cells-possibly because its SGI1 genes are upregulated, they say.
In a separate research project, Carlson identified a Klebsiella strain from turtles that carries a plasmid conferring resistance to the antibiotic ceftriaxone. This antibiotic is the only one approved specifically for treating children with drug-resistant Salmonella infections, yet the incidence of ceftriaxone resistance is rising. "It's an important resistance marker with clinical significance," Carlson says.
Wondering whether protozoa in rumen provide a sanctuary for bacteria to exchange genes encoding antibiotic resistance, Carlson and Rasmussen decided to test this possibility by mixing that drug-resistant strain of Klebsiella with Salmonella strains that were not antibiotic resistant, and then exposing the mixed bacteria to rumen protozoa. The researchers soon recovered ceftriaxone-resistant Salmonella, but no Klebsiella, because the protozoa digested the latter bacteria. "When Klebsiella succumbs to digestion, it releases its ceftriaxone-resistant plasmid, and Salmonella acquires the plasmid," Carlson says.
Ceftriaxone-resistant Salmonella strains also can be recovered from cows, sheep, and goats challenged with that strain of Klebsiella. This proof-of-concept study is the first to document that protozoa in rumen contribute to bacterial gene transfers. Details appear in the January 16, 2006, issue of Veterinary Medicine.
Dioctyl sodium sulfosuccinate (DSS), a surfactant that lyses protozoa, can block both the enhanced virulence of DT104 and transfers of antibiotic-resistant genes from Klebsiella, according to Rasmussen. Periodic treatments, called defaunation, with less-toxic agents could "cleanse animals and eliminate the hidden bacteria," he says. Although DSS is too toxic to be used routinely, researchers are evaluating yucca and coriander plant extracts for their ability to purge cattle and other ruminants of protozoa. Although protozoa boost digestion in the rumen, temporarily removing them does not appear to be harmful to animals.
Each year isolated beef herds develop sporadic Salmonella infections that cause severe diarrhea and deaths. "It's very difficult to totally get rid of sporadic Salmonella once it hits a herd," Carlson says. Defaunation could be evaluated on such herds, he suggests. Moreover, because defaunation reduces methane production by cattle by curbing methanogenic bacteria that also associate with protozoa, "you may get a twofer," in terms of improving food safety and lowering methane fumes, Rasmussen adds. "This disconnect between energy metabolism and cell carbon accumulation can be understood as a consequence of their very slow growth rates," says House, referring to the archaeal cells that he and his col-leagues analyzed. "Almost all of the time, they are not dividing, just slowly metabolizing to maintain." The biological portions of samples from these sites contained mainly crenarchaea, one of the two major groups of archaebacteria.
Carol Potera
The researchers took the samples from sediments that are approximately 40 meters below the sea floor-"where sulfate is being reduced to sulfide, and methane is being oxidized to carbon dioxide," House says. They used several techniques for determining the identity of the living inhabitants, according to team member Jennifer Biddle, a graduate student at Penn State. Thus, they analyzed 16S ribosomal RNA molecules to classify specimens phylogenetically, and also to distinguish between active and dead cells; they analyzed intact polar lipids, which provide another means to distinguish live from fossil cells; and they used fluorescent in situ hybridization methods.
A major impetus behind these studies is their relevance to the search for extraterrestrial life, according to David C. Smith of the University of Rhode Island in Kingston, who was not directly involved in this research. "The basic premise used for studying the marine subsurface is that it may be an analog for subsurface life on other planets," he says. "We argue that if life exists on other planets, it is most likely microbial, and there are reasons to believe that it will be subsurface."
The research is also valuable for illuminating the global methane cycle, according to Stuart Wakeham of the Skidaway Institute of Oceanography, Savannah, Ga. If huge amounts of methane were released into seawater, the global carbon cycle could be thrown out of whack, possibly causing "massive anoxic events in the ocean," he says. Knowledge about methane cycling is also important for understanding global climate change because methane is a greenhouse gas with 25 times the heat-trapping ability of carbon dioxide.
These findings provide important insights about what types of microorganisms reside in deeply buried marine sediments "and, more importantly, how they make their living in this environment," Smith says. "In a broader sense, this work also expands our knowledge of Archaea in general-where they live and what they do." Another value of the research resides in the "number of different types of analyses that were used to study this ecosystem," he adds. "This is an extremely difficult system to work in as the samples do not give up their information very easily. The biomass is low, and the sediment matrix makes the use of routine type sample processing very difficult."
David Holzman

Progress with Efforts To Control Ebola, Marburg Viruses
With the Ebola and Marburg viruses apparently becoming more effective human pathogens, efforts to develop vaccines to protect against these viruses move with a greater sense of urgency. Vaccine developers describe progress on at least two fronts, while an antisense-based therapeutic also appears promising, according to several participants who spoke during the 2005 ASM Biodefense Research Meeting held in Washington, D.C., last February.
One of the experimental vaccines to protect against Ebola consists of two components, a "naked" DNA-based prime step, followed by adenovirusbased booster steps, according to Detrick, Md. That death rate, which far exceeds the 25% death rate observed during the first known outbreak of this virus in Germany nearly 40 years ago, suggests that it is changing.
The Ebola virus also appears to be changing and perhaps is becoming better adapted to humans, according to Nabel. In particular, its outbreak frequency pattern in Africa has gone from once every few years to being nearly annual, suggesting changes in the virus itself or in local ecology that perhaps is affecting species in which the virus resides. Humans likely become infected from contact with nonhuman primates, possibly through eating "bush meat," but the viral reservoir probably involves other species, possibly bats, he says. At least part of Ebola's virulence traces to a surfaceenvelope glycoprotein that is "very toxic to cells" and may also release a "cytokine storm."
The Canadian group designs its VSV-based vaccine to carry versions of the envelope glycoprotein from different Ebola subtypes or Marburg, replacing a VSV-encoded glycoprotein, Feldman says. These vaccines can induce mucosal and systemic immunity, and appear effective in protecting mice, guinea pigs, and also monkeys, which were evaluated at USAMRIID. "All animals were completely protected, while all controls [unvaccinated monkeys] died," he says. That protection was species specific, meaning that the VSV carrying the Marburg-type glycoprotein protected only against Marburg virus, but not Ebola (and vice versa). Though limited, some evidence indicates that the vaccines protect animals, including monkeys, if administered after they are exposed to either type of filovirus.
However, the VSV-based vaccine findings are not entirely straightforward, according to Feldman. For one thing, when mice are inoculated with VSV vectors containing no filovirus glycoproteins, their survival after filovirus challenge is prolonged. "We don't know the mechanism," he says. Moreover, although VSV-vaccinated animals develop both cellular and humoral immune responses, signs of those responses are not apparent until after the animals are subject to filovirus challenges.
Meanwhile, the DNA prime-adenovirus boost experimental vaccine appears to give "durable" protection when tested in guinea pigs. The DNA component of the vaccine, which NIAID researchers are developing in collaboration with Vical of San Diego, Calif., encodes the core protein from the Zaire and surface proteins from the Zaire and Sudan types of Ebola. In a phase 1 clinical trial last year, this DNA vaccine proved safe and well tolerated, according to Julie Martin of NIAID. Vaccinated volunteers produced virus-specific antibodies, which
Recent Noteworthy Developments on the Avian Influenza Front
Public health experts continue to keep close watch over H5N1 avian influenza, which as of mid-March was responsible for causing 103 deaths among 184 human cases of disease, mainly in Asia and Eastern Europe. Other recent developments include:
• One reason H5N1 viruses only poorly infect humans is that only cells that are deep within the lungs carry appropriate receptors for this virus, according to Yoshihiro Kawaoka of the University of Wisconsin, Madison, and his collaborators, whose findings appear in the 23 March issue of Nature.
• Circulating H5N1 viruses now fall into two distinct clades, one associated with outbreaks in mainland Asia and the other associated with outbreaks in Indonesia; the two clades are sufficiently different genetically as to prompt development of separate vaccines, according to Rebecca Garten of the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga, who presented findings during the International Conference on Emerging Infectious Diseases in March.
• With a goal of preserving the clinical effectiveness of two specific classes of antiviral drugs, officials of the Food and Drug Administration in March issued a provisional rule to prohibit the use of several such drugs in poultry; specifically, the order prohibits veterinarians from using amantadine and rimantadine as well as the neuraminidase inhibitors oseltamivir and zanamivir, in chickens, turkeys, and ducks. peak 12 weeks after being inoculated, as well as cellular immune responses, she says.
In a separate development, a series of antisense oligomers-specifically, phosphorodiamidate morpholino oligomers (PMOs)-proved effective at inhibiting the cytopathic effects of Ebola viruses when tested in Vero cells, according to Kelly Warfield of USAMRIID. The PMOs, which delay viral replication, also protect guinea pigs against Ebola virus challenge and prolong survival of macaque monkeys after they are exposed to lethal doses of the virus. "A genespecific therapeutic for Ebola is within reach," she says.
Jeffrey L. Fox
Vancomycin Analog Shows Promise Pitted against Resistant Pathogens
Vancomycin-resistant Enterococcus faecalis is considered one of the most dangerous pathogens because of its ability to withstand this antibiotic of "last resort." However, a redesigned vancomycin analog could turn the tables on this pesky pathogen, effectively restoring sensitivity by molecularly tweaking vancomycin, according to a group of medicinal chemists at the Scripps Research Institute in La Jolla, Calif., and their collaborators.
"Our successful synthesis of a novel vancomycin analog could potentially lead to a new generation of antibiotics," says organic chemist Dale Boger, who revamped vancomycin with the help of graduate student Brendan Crowley. "Vancomycin is a very complex molecule, yet we made a very subtle change."
Based on a detailed understanding of what enables pathogens to develop resistance to this antibiotic, Boger and Crowley converted a vancomycin carbonyl group to a methylene. This seemingly simple chemical change required a challenging 24-step synthesis process to generate the new analog. "It's amazing that one graduate student accomplished all of this," Boger says. For the record, vancomycin is a branched, tricyclic glycosylated peptide with a molecular weight of 1,449.
Vancomycin acts by mimicking, binding to, and blocking further synthesis of a peptidoglycan that makes up bacterial cell walls. Bacteria typically develop resistance to this antibiotic through a mutation that substitutes D-lactate for the usual D-alanine that is part of the peptidoglycan, reducing vancomycin's effectiveness by about 1,000-fold. Boger attributes this reduced effectiveness to a loss in drug affinity through chemically localized destabilization caused by lonepair electronic repulsion. Substituting a methylene for a carbonyl group in vancomycin counters this destabilizing lone-pair interaction, restoring binding affinity and biological activity that the parent antibiotic had lost.
Moreover, the methylene compound not only is effective against Dlactate-containing, vancomycin-resistant bacteria, but it also binds to and is effective against vancomycin-sensitive bacteria with D-alanine in their cell walls. When the researchers tested the methylene-containing analog against VanA E. faecalis, a highly resistant strain, they found that it proved 100-fold more powerful than vancomycin in vitro, whereas its potency was about 30-fold weaker against vancomycin-sensitive E. faecalis. Additional details are provided in the March 8, 2006, issue of the Journal of the American Chemical Society.
"For it to be an ideal drug, we need to increase its potency for sensitive bacteria at least 10-fold," Boger says. Furthermore, because synthesizing the molecule from scratch is impractical for large-scale production, Boger plans to explore ways to produce the analog by chemically modifying vancomycin or by using a microorganism to generate the analog or a precursor.
Microbiologist Lynn Silver, an independent pharmaceutical consultant in Springfield, N.J., describes the redesign of vancomycin as "really excellent work." The new analog, an aglyNewly Computed "Tree of Life" Rearranges Several Microbial Branches A new computational approach, which focuses on 31 "universally occurring genes with indisputable orthology in 191 species with completely annotated genomes," is being used to analyze relationships among those species. It leads to some interesting rearrangements in the microbial branches of the universal "tree of life," according to Peer Bork of the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and his collaborators. For instance, the Firmicutes within the Bacteria segment appear to be the earliest-branching phylum in this new scheme, a finding that supports an earlier hypothesis that Bacteria has its origins in a gram-positive species. Other results suggest that the last universal common ancestor was a thermophile. More broadly, if microbial standards were applied to eukaryotes, more of them would belong to the same phylum. Moreover, smaller genomes appear to evolve more rapidly, and this generalization applies not only to pathogens and endosymbionts but also to free-living microbial species and eukaryotes. Additional details appear in the 3 March 2006 issue of Science. con, still needs to have its carbohydrate groups added, she notes, before the method is truly perfected. "The concept of changing the internal structure of vancomycin is something that people have thought about for a long time," she says. The approach changes the pathogen and drug interactions, making it unlikely for resistance to occur again.
